# Ginsenosides in Modern Pharmaceutics: Mechanisms, Applications, Challenges, and Perspectives

**Authors:** Mingyang Sun, Youduan Li, Ming Zhu, Haoming Luo, Ye Teng

PMC · DOI: 10.3390/biom16030350 · Biomolecules · 2026-02-26

## TL;DR

This review explores ginsenosides' mechanisms, applications, and challenges in treating diseases like cancer and diabetes, while proposing innovative solutions for their limitations.

## Contribution

The paper systematically discusses innovative solutions like nanodelivery and AI-driven design to overcome ginsenosides' bioavailability and safety challenges.

## Key findings

- Ginsenosides show promise in treating neurodegenerative diseases, cancer, and metabolic disorders.
- Nanodelivery systems and structural modifications may enhance ginsenosides' bioavailability and brain permeability.
- High-quality clinical evidence and long-term safety data remain lacking for ginsenosides.

## Abstract

Ginsenosides are the primary bioactive constituents of Panax ginseng, exhibiting multiple pharmacological activities, including neuroprotection, antitumor effects, anti-aging properties, and metabolic regulation. In this review, the molecular mechanisms of ginsenosides in treating neurodegenerative diseases, cancer, and metabolic disorders are summarized, and the current status of clinical translational research on ginsenosides in advanced gastric cancer, breast cancer, stroke, and diabetes is introduced, incorporating critical evidence regarding safety assessments and potential toxicity risks. In addition, recent advances in biotransformation and modern preparation technologies are reviewed. Innovative solutions, including nanodelivery systems, structural modifications, and AI-driven formulation design, are systematically discussed to address the current issues, such as low oral bioavailability and limited blood–brain barrier permeability. The future development of ginsenosides continues to face several critical challenges, including a scarcity of high-quality clinical evidence, an incomplete understanding of their mechanisms of action, a dearth of long-term safety data, and variations in quality between batches.

## Linked entities

- **Chemicals:** ginsenosides (PubChem CID 3086007)
- **Diseases:** cancer (MONDO:0004992), gastric cancer (MONDO:0001056), breast cancer (MONDO:0004989), stroke (MONDO:0005098), diabetes (MONDO:0005015)
- **Species:** Panax ginseng (taxon 4054)

## Full-text entities

- **Diseases:** metabolic disorders (MESH:D008659), cancer (MESH:D009369), breast cancer (MESH:D001943), stroke (MESH:D020521), toxicity (MESH:D064420), gastric cancer (MESH:D013274), diabetes (MESH:D003920), neurodegenerative diseases (MESH:D019636)
- **Chemicals:** Ginsenosides (MESH:D036145)
- **Species:** Panax ginseng (Asiatic ginseng, species) [taxon 4054]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13024219/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13024219/full.md

## References

138 references — full list in the complete paper: https://tomesphere.com/paper/PMC13024219/full.md

---
Source: https://tomesphere.com/paper/PMC13024219